Johnson & Johnson posted a 6.5% increase in third quarter sales of $17.1 billion. Operational results increased 10.8% and the negative impact of currency was 4.3%. Domestic sales increased 13.4%, while international sales increased 1.4%.
Positive contributors to operational results were international sales of Listerine oral care products and Neutrogena skin care products, said the company.
“Our third-quarter results reflected continued sales momentum driven by strong growth of key products, successful new product launches, and the addition of Synthes to our family of companies. We advanced our pipelines with regulatory approvals for a number of new products, the submission of several new drug applications, and the completion of several strategic collaborations,” said Alex Gorsky, chief executive officer.“I’m extremely proud of our talented and dedicated colleagues throughout Johnson & Johnson and I have great confidence in our ability to deliver sustainable growth and bring meaningful innovations to patients and customers around the world.”